Toft Group Completes Executive Search for Retrophin (NASDAQ: RTRX) in San Diego, CA


Executive search firm Toft Group has placed Gayle Bresnahan as Associate Director, Clinical Operations at Retrophin in San Diego, CA. Ms. Bresnahan offers 20 years of clinical research within Oncology, Diabetes, Nephrology, Neurology and Infectious Disease therapeutic areas. She most recently served at Intercept Pharmaceuticals as Associate Director, Clinical Operations, where she was responsible for project management and execution of Phase II and III non-viral liver disease studies. Ms. Bresnahan received her BS in Business Administration from Bristol University.

About Retrophin

Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in additional rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products Thiola®, Cholbam® and Chenodal®.